TABLE 2.
Antiviral activity of other representative tylophorine analogues.
| Comp | Anti-TMV Activity (500 mg/L) | Ref | |||
|---|---|---|---|---|---|
| Concentration (mg/L) | Curative (%) | Protective (%) | Inactivating (%) | ||
| 55 | 500 | 69.6 | 72.7 | 72.2 | Wang et al. (2012a) |
| 56 | 500 | 36.6 | 39.5 | 42.1 | Wang et al. (2012b) |
| 57 | 500 | 67.9 | 63.7 | 57.8 | Wang et al. (2012c) |
| 58 | 500 | 81 | 84 | - | Wang et al. (2010b) |
| 59 | 500 | 37.4 | 70.8 | 71.1 | Wang et al. (2014a) |
| 60 | 500 | 65.8 | 69.2 | 70.3 | Su et al. (2021) |
| 61 | 500 | 58.6 | 54.1 | 55.8 | Su et al. (2014b) |
| 62 | 500 | 68.1 | 69.3 | 63.2 | Wu et al. (2014) |
| 63 | 500 | 56 | 53 | 57 | Yu et al. (2016) |
| 64 | 500 | 82.1 | 77.6 | 76.6 | Han et al. (2018) |
| 65 | 500 | 49.4 | 55.3 | 52.6 | Wang et al. (2014b) |
| 66 | 500 | 66 | 71 | 68 | Li et al. (2018) |
| 67 | 500 | 44 | 42.3 | 40.5 | Wu et al. (2013) |